Phase 2Active, not recruiting
Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema
A Phase 2, Multicenter, Randomized, Double-Masked, Parallel-Group Study to Assess the Efficacy and Safety of KHK4951, a Vascular Endothelial Growth Factor Receptor Inhibitor, in Patients With Diabetic Macular Edema
- Sponsor
- Kyowa Kirin Co., Ltd. (Industry)
- Enrolment
- 185 enrolled
- Conditions
- Diabetic Macular Edema (DME)
- Interventions
- KHK4951; Aflibercept Injection
- Ages
- adults, older adults
- Registry
- NCT06116916
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to evaluate efficacy and safety of KHK4951 eye drops in patients with DME.
Primary outcomes
- Reduction of 15 or more letters in BCVA (Best corrected visual acuity) as measured by ETDRS visual acuity chart from baseline
History
Study completion expected
Primary completion expected
Last registry update
Started
Registered